Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT00141700
Phase
PHASE2
Status
Terminated

Conditions

  • Lymphoma, Non-Hodgkin's

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, stem cell support and Rituximab (which is a form of immunotherapy).

Key Dates

First listed
Sep 1, 2005
Start date
Mar 31, 2003
Status verified
Dec 2007
Primary completion
Mar 31, 2005
Completion
Dec 31, 2005

Study Design

Enrollment
30 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Assess progression-free survival after rituximab and high-dose chemotherapy with autologous PBPC support;

Locations (1)

FacilityCityStateZIPSite coordinators
The University of MichiganAnn ArborMichigan48109-

Find similar trials in Ann Arbor, MI

By research site
The University of Michigan· Ann Arbor, MI

Related Studies